血清钙化倾向与CKD临床事件
在3404例CKD 2-4期患者中,评估血清钙化倾向(T50)与动脉粥样硬化性心血管疾病、心力衰竭、ESKD及全因死亡的关系。平均随访7.1年,较低T50与动脉粥样硬化性心血管疾病、3年内ESKD和全因死亡风险升高相关,但校正eGFR和24小时尿蛋白后关联不再显著。
要点
- 较低T50(高钙化倾向)与动脉粥样硬化性心血管疾病事件风险升高相关。
- 较低T50与3年内ESKD和全因死亡风险升高相关,但与心力衰竭无关。
- 校正eGFR和24小时尿蛋白后,T50与上述结局的关联均不再显著。
核心结论
- CKD 2-4期患者中,较高血清钙化倾向与动脉粥样硬化性心血管疾病事件、ESKD和全因死亡相关,但该关联不独立于肾功能。
研究设计与样本
- 前瞻性纵向慢性肾功能不全队列研究,纳入3404例CKD 2-4期参与者。
- 钙化倾向以T50(原发向继发性钙蛋白颗粒转化时间)量化,T50越低钙化倾向越高。
- 采用多变量校正Cox比例风险回归模型评估T50与结局的关联。
主要发现
- 平均T50为313(SD 79)分钟。
- 平均随访7.1(SD 3.1)年,观察到571例动脉粥样硬化性心血管疾病事件、633例心力衰竭事件、887例ESKD事件和924例死亡。
- 校正传统心血管疾病危险因素后,T50每降低1个SD与动脉粥样硬化性心血管疾病风险升高相关(HR 1.14;95%CI 1.05至1.25)。
- 校正传统心血管疾病危险因素后,T50每降低1个SD与基线起3年内ESKD风险升高相关(HR 1.68;95%CI 1.52至1.86)。
- 校正传统心血管疾病危险因素后,T50每降低1个SD与全因死亡风险升高相关(HR 1.16;95%CI 1.09至1.24),但与心力衰竭无关(HR 1.06;95%CI 0.97至1.15)。
临床怎么用
- 血清钙化倾向T50可作为CKD 2-4期患者心血管和肾脏结局的风险标志物,但需结合肾功能评估。
- T50与结局的关联不独立于eGFR和尿蛋白,提示其风险信息可能部分由肾功能介导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients with CKD are at high risk for cardiovascular disease, ESKD, and mortality. Vascular calcification is one pathway through which cardiovascular disease risks are increased. We hypothesized that a novel measure of serum calcification propensity is associated with cardiovascular disease events, ESKD, and all-cause mortality among patients with CKD stages 2-4. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Among 3404 participants from the prospective, longitudinal Chronic Renal Insufficiency Cohort Study, we quantified calcification propensity as the transformation time (T50) from primary to secondary calciprotein particles, with lower T50 corresponding to higher calcification propensity. We used multivariable-adjusted Cox proportional hazards regression models to assess the associations of T50 with risks of adjudicated atherosclerotic cardiovascular disease events (myocardial infarction, stroke, and peripheral artery disease), adjudicated heart failure, ESKD, and mortality. RESULTS: The mean T50 was 313 (SD 79) minutes. Over an average 7.1 (SD 3.1) years of follow-up, we observed 571 atherosclerotic cardiovascular disease events, 633 heart failure events, 887 ESKD events, and 924 deaths. With adjustment for traditional cardiovascular disease risk factors, lower T50 was significantly associated with higher risk of atherosclerotic cardiovascular disease (hazard ratio [HR] per SD lower T50, 1.14; 95% confidence interval [95% CI], 1.05 to 1.25), ESKD within 3 years from baseline (HR per SD lower T50, 1.68; 95% CI, 1.52 to 1.86), and all-cause mortality (HR per SD lower T50, 1.16; 95% CI, 1.09 to 1.24), but not heart failure (HR per SD lower T50, 1.06; 95% CI, 0.97 to 1.15). After adjustment for eGFR and 24-hour urinary protein, T50 was not associated with risks of atherosclerotic cardiovascular disease, ESKD, and mortality. CONCLUSIONS: Among patients with CKD stages 2-4, higher serum calcification propensity is associated with atherosclerotic cardiovascular disease events, ESKD, and all-cause mortality, but this association was not independent of kidney function. PODCAST: This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_10_28_CJN04710419.mp3.
引用
- Bundy JD, Cai X, Mehta RC, et al. Serum Calcification Propensity and Clinical Events in CKD. Clin J Am Soc Nephrol. 2019. PMID: 31658949. doi:10.2215/CJN.04710419
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。